Biopharma doubles down on immunology and inflammation as companies target new pathways and seek to improve on current options ...
2don MSN
In 2024, combined Skyrizi and Rinvoq sales reached $17.7 billion, up 51% year over year, reflecting accelerating global ...
Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...
AbbVie appoints CEO Robert A Michael as chairman of the board of directors: North Chicago, Illinois Monday, February 17, 2025, 13:00 Hrs [IST] AbbVie announced that its board of d ...
UBS initiated coverage of Alvotech (ALVO) with a Buy rating and $18 price target Alvotech is a pure-play biosimilar company, with a ...
Just as Andrew Witty of UnitedHealth Group did in a call with investors last month, CVS Health’s CEO David Joyner defended ...
The second part of our conversation with Craig Burton, MBA, executive director of the Biosimilars Council, a trade and ...
Novartis' Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of its multi-billion dollar revenues once its patent expires. The generics and biosimilars arm of ...
Biogen (NASDAQ:BIIB – Free Report) had its price target trimmed by HC Wainwright from $300.00 to $241.00 in a report issued ...
CVS Health is seeing signs of stabilization in key business areas, prompting Leerink Partners to upgrade the stock from Market Perform to Outperform and raise its price target to $75 per share in a ...
UBS analysts maintained a Buy rating for Alvotech SA (NASDAQ:ALVO) with a steady price target of $18.00, representing a 41% ...
Biogen (NASDAQ:BIIB – Free Report) had its target price lowered by Truist Financial from $220.00 to $210.00 in a research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results